

SHINGRIX INFORMATION & IMPLEMENTATION

A GUIDE FOR NURSES & OFFICE STAFF




SHINGRIX

(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).



UNDERSTANDING SHINGLES RISK



Shingles is a painful, blistering rash caused by the varicella zoster virus (VZV), the same virus that causes chickenpox. The rash typically develops on one side of the face or body. Most people associate shingles with the telltale painful rash, but there can also be serious, long-lasting complications.¹⁻³

99% of people 50 years of age and older are infected with VZV. In **1 out of 3 people**, the dormant virus reactivates and causes shingles.^{2,4}

A dominant driver of shingles is age-related decline in immunity, or ARDI.^{2,5-9}

- Increasing age causes a natural decline in immunity
- As immune function declines, there is a reduction in the number and functionality of immune cells that prevent reactivation of VZV
- ARDI leads to a sharp increase in the incidence and severity of shingles



He's pretty healthy, but he's over 50 years of age. No matter how much he exercises or how good his diet is, he's still at risk for shingles.²

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at [SHINGRIXHCP.com](#).

HELPING YOUR DOCTOR PROTECT PATIENTS AGAINST SHINGLES



- Review medical records to identify appropriate patients
- Inform patients that they may be eligible to receive SHINGRIX
- Provide patient-friendly handout information about SHINGRIX
- Confirm insurance coverage for patient



Important Safety Information (cont'd)

- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at [SHINGRIXHCP.com](#).


INFORMING PATIENTS OF POSSIBLE ADVERSE EVENTS



Patients will want to know what kind of side effects they may experience with SHINGRIX. Let them know that:

“Side effects can include pain, redness, and swelling at the injection site. You may also experience muscle pain, fatigue, headache, shivering, fever, or upset stomach.”¹⁰

“The local and general adverse reactions seen with SHINGRIX had a median duration of 2 to 3 days.”¹⁰



Important Safety Information (cont'd)

- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at [SHINGRIXHCP.com](#).


REMINDING PATIENTS TO RETURN FOR THEIR SECOND DOSE



SHINGRIX is given as a 2-dose series. The second dose should be given 2 to 6 months after the first dose is received. Remind patients that the second dose of SHINGRIX is not a nice-to-have, it's an important-to-have—and you want to ensure they receive theirs.¹⁰

Encourage your patients to sign up for second dose reminders at SHINGRIXreminder.com

Find more helpful resources for your patients at SHINGRIXHCP.com



“It’s important to get both doses—you can schedule a second dose reminder email or phone call with our office. You can also sign up for a second dose reminder text message at SHINGRIXreminder.com.”

Important Safety Information (cont'd)

- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at SHINGRIXHCP.com.

ADDRESSING PATIENT COST CONCERNS



SHINGRIX is \$0 for almost everyone 50 years and older.^{11-13,*}

95% of commercial patients pay \$0 for SHINGRIX, with average copays of just \$4 or less.^{11,12,*,+}

All Medicare Part D patients can receive SHINGRIX for \$0 at their pharmacy.^{11,13}

*Coverage and cost may vary and are subject to change without notice. Reimbursement decisions are made by individual insurance plans.

+SOURCE: Managed Markets Insight & Technology, LLC, Database as of October 2022. Coverage represents access to reimbursement from a health plan with restrictions appropriate to the Advisory Committee on Immunization Practices (ACIP) recommendation(s) and/or prescribing information. Veterans Affairs (VA) and Indian Health Service (IHS) lives have been omitted when calculating the percentage of lives.



“My doctor recommended SHINGRIX. Is it covered by my health insurance?”

“Most adults 50 years and older are covered for SHINGRIX. If you have private insurance, you’ll typically pay no out-of-pocket cost per dose. If you’re covered under Medicare Part D, you can receive SHINGRIX for \$0 at the pharmacy.”^{11,13}



“My doctor mentioned I could get SHINGRIX at a pharmacy?”

“As with flu vaccines, you can get SHINGRIX at a pharmacy. If any of your in-network pharmacies don’t carry it, you can also visit [scheduleSHINGRIX.com](https://www.scheduleSHINGRIX.com). Let us know when you have received either of the doses.”

Important Safety Information (cont'd)

- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at [SHINGRIXHCP.com](https://www.SHINGRIXHCP.com).

ORDERING

Getting SHINGRIX for your office is simple when ordering through either your preferred wholesale distributor or [GSKdirect.com](https://www.gskdirect.com).

BILLING, CODING, AND INSURANCE	
CPT Code (Product)	90750
CPT Code (Administration) 1 vaccine administered	90471
Each additional vaccine administered during same encounter	90472
ICD-10-CM Code (Encounter for Immunization)	Z23
Administration Modifier for Medicare	GY
MVX Code	SKB
CVX Code	187

GSK has removed SHINGRIX ordering caps and is currently meeting demand across all distribution channels. You are encouraged to order through whichever channel you prefer to help meet your SHINGRIX needs.


Please see **Important Safety Information** throughout and [click here](#) for full **Prescribing Information** for SHINGRIX, also available at [SHINGRIXHCP.com](https://www.shingrixhcp.com).



CREATING A PLAN



Use this helpful checklist for successful implementation of SHINGRIX in your practice:



- Does your practice accommodate SHINGRIX vaccinations in office?
 - If so, what age-group do you vaccinate?
- Do you refer any patients to the pharmacy? If so, which kinds of patients?
- If referred to a pharmacy, what does a proper referral look like, and how do you follow up with patients who received their vaccine at the pharmacy?
 - Are you satisfied with the number of patients you refer to the pharmacy who follow through with their vaccination?
 - If not, would providing an eRx help?
- Do you have the tools to check insurance coverage for your patients?
 - What are they?
 - How do you go about checking insurance coverage?

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

- SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
- Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
- In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
- Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

Important Safety Information (cont'd)

- Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
- Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
- The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
- It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
- Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see Important Safety Information throughout and [click here](#) for full Prescribing Information for SHINGRIX, also available at [SHINGRIXHCP.com](#).



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

REFERENCES

1. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. *BMJ Open*. 2014;4(6):e004833. 2. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2008;57(RR-5):1-30. 3. Centers for Disease Control and Prevention. Shingles cause and transmission. Updated May 10, 2023. Accessed August 18, 2023. <https://www.cdc.gov/shingles/about/transmission.html> 4. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. *J Med Virol*. 2003;70(suppl 1):S111-S118. 5. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. *N Engl J Med*. 2007;356(13):1338-1343. 6. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. *Curr Opin Immunol*. 2012;24(4):494-500. 7. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. *Vaccine*. 2014;32(15):1745-1753. 8. Patterson-Bartlett J, Levin MJ, Lang N, et al. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. *Vaccine*. 2007;25(41):7087-7093. 9. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus—specific cell-mediated immune responses. *J Infect Dis*. 2010;201(7):1024-1030. 10. Prescribing Information for SHINGRIX. 11. Data on file, GSK. 12. Managed Markets Insight & Technology, LLC, Database as of October 2022. 13. Kirchhoff SM. Selected Health Provisions of the Inflation Reduction Act. Congressional Research Service. 2022;1-3. Accessed November 16, 2022. <https://crsreports.congress.gov/product/pdf/IF/IF12203>



SHINGRIX
(ZOSTER VACCINE
RECOMBINANT, ADJUVANTED)

Trademarks are owned by or licensed to the GSK group of companies.



©2023 GSK or licensor.
SGXLBND230012 August 2023
Produced in USA.